FOBs: White House Says 7 Years Of Exclusivity Is "Generous Compromise"
Executive Summary
Rep. Henry Waxman, D-Calif., probably had a pretty good moment at his mailbox last week: he got a 1letter from the White House essentially endorsing his approach to follow-on biologics
You may also be interested in...
Follow-on Biologics: As Mark-Ups Loom, What's Waxman's End Game?
Coming to an abrupt halt after racing at full speed is never easy, but that seems to be the best play available to generic advocates of a legislative pathway for follow-on biologics
NORD Refines Orphan Exclusivity Position
Second letter to Waxman suggests that all orphan biologics should get nine years of exclusivity, noting the "challenge to innovation" posed by untreated rare diseases.
Follow-on Biologics: As Mark-Ups Loom, What's Waxman's End Game?
Coming to an abrupt halt after racing at full speed is never easy, but that seems to be the best play available to generic advocates of a legislative pathway for follow-on biologics